Clinical Trials Logo

Filter by:
NCT ID: NCT01268059 Terminated - Clinical trials for Non-small Cell Lung Cancer

A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer

Start date: December 16, 2010
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate the dose, antitumor activity, safety and pharmacology of MEDI-575 in combination with carboplatin/paclitaxel in subjects with previously untreated, advanced non-small cell lung cancer (NSCLC).

NCT ID: NCT01267578 Recruiting - Esophageal Cancer Clinical Trials

Peptide Vaccination in Treating Patients With Esophageal Cancer (STF-II)

Start date: April 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate overall survival and immunological monitoring for peptide vaccination therapy using novel cancer testis antigens (STF-II) for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma

NCT ID: NCT01266746 Completed - Macular Hole Clinical Trials

Optical Coherence Tomography in Gas-filled Eyes

Start date: April 2009
Phase: N/A
Study type: Observational

The aim of this study is to determine the condition to detect the status of a macular hole by spectral domain optical coherence tomography (SD-OCT) in gas-filled eyes. The macular area is scanned by SD-OCT (OCT-4000, Carl Zeiss Meditec) in the patients who underwent vitreous surgery for macular hole to detect macular jole closure on postoperative days 1, 3, 7, and 30.

NCT ID: NCT01266720 Active, not recruiting - Pancreatic Cancer Clinical Trials

HLA-A*0201 Restricted Peptide Vaccine Therapy With Gemcitabine With Gemcitabine in Patient Pancreatic Cancer (Phase1)

Start date: April 2008
Phase: Phase 1
Study type: Interventional

The purpuse of this study is to assess toxicities of angiogenic peptide vaccine therapy with gemcitabine in treating HLA-A*0201 restricted patient with non-resectable pancreatic cancer.

NCT ID: NCT01266707 Recruiting - Clinical trials for Hepatocellular Carcinoma

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.

NCT ID: NCT01266239 Recruiting - Clinical trials for Ischemic Heart Disease

Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion

J-REVERSE
Start date: July 2010
Phase: N/A
Study type: Interventional

In study-1, the purpose of this study is to compare the long-term outcome of provisional stenting between EES and SES deployment. In study-2, it is to prove the following hypothesis " Asymmetrical expansion in the bifurcation lesion leads to frequent inhomogeneous intimal growth on the strut and thrombus attachment."

NCT ID: NCT01264822 Completed - Clinical trials for Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive

Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori

Start date: January 13, 2011
Phase: N/A
Study type: Observational

To survey the grade of gastric MALT lymphoma after eradication of Helicobacter pylori

NCT ID: NCT01263470 Completed - Clinical trials for Diabetes Mellitus, Type 2

Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes in Japan

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study was to evaluate the dose-response relationships of alogliptin, once daily (QD) to an α-glucosidase inhibitor, three times daily (TID), to determine the optimal clinical dose for type 2 diabetic patients.

NCT ID: NCT01262274 Terminated - Breast Neoplasms Clinical Trials

Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer

Neo-ACET BC
Start date: December 2010
Phase: Phase 2
Study type: Interventional

The Aim of this study is to validate a treatment of anastrozole in combination with tegafur-uracil as pre-operative therapy for postmenopausal primary breast cancer. Although pre-operative hormone therapy is a novel therapeutic approach, only hormone therapy has limitation in terms of efficacy. Metronomic chemotherapy, which is the frequent administration of low-dose cytotoxic agents, is not only target tumor cells but also inhibiting angiogenesis. Because there was a report that efficacy of hormone therapy add to metronomic chemotherapy as pre-operative therapy, a randomized phase II trial of anastrozole (ANA) in combination with/without metronomic tegafur-uracil (UFT) as neo-adjuvant for postmenopausal breast cancer will be conducted.

NCT ID: NCT01261572 Completed - Prostatic Neoplasms Clinical Trials

Study to Find Maintenance Dose for Periodic Administration of ASP3550

Start date: October 12, 2010
Phase: Phase 2
Study type: Interventional

To find effective doses of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer.